IL149496A0 - Pharmaceutical combinations and their use in treating gastrointestinal disorders - Google Patents

Pharmaceutical combinations and their use in treating gastrointestinal disorders

Info

Publication number
IL149496A0
IL149496A0 IL14949600A IL14949600A IL149496A0 IL 149496 A0 IL149496 A0 IL 149496A0 IL 14949600 A IL14949600 A IL 14949600A IL 14949600 A IL14949600 A IL 14949600A IL 149496 A0 IL149496 A0 IL 149496A0
Authority
IL
Israel
Prior art keywords
gastrointestinal disorders
pharmaceutical combinations
treating gastrointestinal
treating
pharmaceutical
Prior art date
Application number
IL14949600A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL149496A0 publication Critical patent/IL149496A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL14949600A 1999-12-10 2000-12-08 Pharmaceutical combinations and their use in treating gastrointestinal disorders IL149496A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45838899A 1999-12-10 1999-12-10
PCT/EP2000/012420 WO2001041748A2 (en) 1999-12-10 2000-12-08 Pharmaceutical combinations and their use in treating gastrointestinal disorders

Publications (1)

Publication Number Publication Date
IL149496A0 true IL149496A0 (en) 2002-11-10

Family

ID=23820591

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14949600A IL149496A0 (en) 1999-12-10 2000-12-08 Pharmaceutical combinations and their use in treating gastrointestinal disorders
IL149496A IL149496A (en) 1999-12-10 2002-05-06 Pharmaceutical compositions and their use in the treatment of the gastrointestinal tract

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL149496A IL149496A (en) 1999-12-10 2002-05-06 Pharmaceutical compositions and their use in the treatment of the gastrointestinal tract

Country Status (30)

Country Link
EP (3) EP1488788A1 (da)
JP (1) JP2003523324A (da)
KR (1) KR100765579B1 (da)
CN (2) CN1310644C (da)
AR (1) AR026916A1 (da)
AT (1) ATE293971T1 (da)
AU (2) AU778869B2 (da)
BR (1) BR0016275A (da)
CA (1) CA2388959A1 (da)
CO (1) CO5261535A1 (da)
CZ (1) CZ300690B6 (da)
DE (1) DE60019814T2 (da)
DK (1) DK1286668T3 (da)
ES (1) ES2240229T3 (da)
HU (1) HUP0301122A3 (da)
IL (2) IL149496A0 (da)
MX (1) MXPA02005695A (da)
MY (1) MY133423A (da)
NO (1) NO20022680L (da)
NZ (2) NZ531489A (da)
PE (1) PE20011030A1 (da)
PL (1) PL202201B1 (da)
PT (1) PT1286668E (da)
RU (1) RU2264215C2 (da)
SG (1) SG152025A1 (da)
SK (1) SK8062002A3 (da)
TR (1) TR200402293T2 (da)
TW (1) TWI263496B (da)
WO (1) WO2001041748A2 (da)
ZA (1) ZA200204493B (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1284732A2 (en) * 2000-05-18 2003-02-26 Glaxo Group Limited Method for treating functional dyspepsia using alosetron
GB0209481D0 (en) * 2002-04-24 2002-06-05 Novartis Ag Organic compounds
JP2006516977A (ja) 2003-01-13 2006-07-13 ダイノゲン ファーマシューティカルズ，インコーポレイテッド 悪心、嘔吐、レッチング、またはそれらの任意の組み合わせの治療方法
GB0307440D0 (en) * 2003-03-31 2003-05-07 Novartis Ag Organic compounds
WO2004105795A1 (en) * 2003-05-27 2004-12-09 Altana Pharma Ag Pharmaceutical combinations of a proton pump inhibitor and a compound which modifies gastrointestinal motility
US20050090554A1 (en) * 2003-09-12 2005-04-28 John Devane Treatment of gastroparesis and nonulcer dyspepsia with GABAB agonists
US7820690B2 (en) 2004-03-19 2010-10-26 Solvay Pharmaceuticals Gmbh Method of treating or inhibiting a non-digestive tract derived abdominal disorder associated with pain using a 5-HT, receptor antagonist
AU2005261778A1 (en) * 2004-07-14 2006-01-19 Novartis Ag Combination of DPP-IV inhibitors and compounds modulating 5-HT3 and/or 5-HT4 receptors
AU2006211205A1 (en) * 2005-01-31 2006-08-10 Novartis Ag Organic compounds
GB0506800D0 (en) * 2005-04-04 2005-05-11 Merck Sharp & Dohme New uses
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
JP2009525269A (ja) 2006-01-30 2009-07-09 ユーロ−セルティーク エス．エイ． カルシウムチャネルブロッカーとしての環状尿素化合物
CN101466368A (zh) * 2006-06-15 2009-06-24 诺瓦提斯公司 用于治疗或者预防胃损伤的仅包括替加色罗或者包括替加色罗与质子泵抑制剂组合的组合物
CN101657436A (zh) 2007-02-09 2010-02-24 特兰齐姆制药公司 大环生长素释放肽受体调节剂及其使用方法
US8865692B2 (en) 2007-11-13 2014-10-21 Meritage Pharma, Inc Compositions for the treatment of gastrointestinal inflammation
US20090149433A1 (en) 2007-11-13 2009-06-11 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
US11858996B2 (en) 2016-08-09 2024-01-02 Kymab Limited Anti-ICOS antibodies
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
EP3728314A1 (en) 2017-12-19 2020-10-28 Kymab Limited Bispecific antibody for icos and pd-l1
TW202313682A (zh) 2021-05-18 2023-04-01 英商凱麥博有限公司 抗icos抗體之用途
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
WO2023222854A1 (en) 2022-05-18 2023-11-23 Kymab Limited Uses of anti-icos antibodies
FR3144752A1 (fr) 2023-01-10 2024-07-12 Song Huang Utilisation de polysulfate de pentosane pour le traitement de la toux seche

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362756A (en) * 1989-02-20 1994-11-08 Riviere Pierre J M Use of fedotozine in the treatment of functional states of intestinal obstructions
HUT64023A (en) * 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
DE69226961T2 (de) * 1991-12-21 1999-04-29 Smithkline Beecham P.L.C., Brentford, Middlesex Verwendung von 5-ht4 - antagonisten zur herstellung eines arzneimittels zur behandlung von harninkontinenz
GB9214184D0 (en) * 1992-07-03 1992-08-12 Smithkline Beecham Plc Pharmaceuticals
US5932568A (en) * 1994-11-21 1999-08-03 Dainippon Pharmaceutical Co., Ltd. 6-methoxy-1H-benzotriazole-5-carboxamide derivatives and pharmaceutical compositions containing them
US5919760A (en) * 1996-04-12 1999-07-06 Intensive Narcotic Detoxification Centers Of America, Llc Method for treating acute and severe diarrhea
US6156771A (en) * 1997-08-28 2000-12-05 Rubin; Walter Method for alleviation of lower gastrointestinal disorders in a human patient
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
CN1409634A (zh) 2003-04-09
EP1286668A2 (en) 2003-03-05
ES2240229T3 (es) 2005-10-16
ATE293971T1 (de) 2005-05-15
SG152025A1 (en) 2009-05-29
BR0016275A (pt) 2002-08-27
JP2003523324A (ja) 2003-08-05
KR20030016208A (ko) 2003-02-26
RU2002118316A (ru) 2004-02-20
CO5261535A1 (es) 2003-03-31
PL355663A1 (en) 2004-05-04
TWI263496B (en) 2006-10-11
CZ20021967A3 (cs) 2002-08-14
HUP0301122A2 (hu) 2003-08-28
AU2005200797A1 (en) 2005-03-17
EP1286668B1 (en) 2005-04-27
CZ300690B6 (cs) 2009-07-15
EP1488788A1 (en) 2004-12-22
MXPA02005695A (es) 2002-09-18
PL202201B1 (pl) 2009-06-30
CN1875966A (zh) 2006-12-13
PT1286668E (pt) 2005-08-31
KR100765579B1 (ko) 2007-10-09
DK1286668T3 (da) 2005-08-15
NO20022680D0 (no) 2002-06-06
ZA200204493B (en) 2003-09-29
AR026916A1 (es) 2003-03-05
NZ566800A (en) 2009-11-27
CN1310644C (zh) 2007-04-18
DE60019814D1 (de) 2005-06-02
AU778869B2 (en) 2004-12-23
AU2672801A (en) 2001-06-18
NZ531489A (en) 2005-09-30
AU2005200797B2 (en) 2008-01-24
WO2001041748A3 (en) 2002-12-19
SK8062002A3 (en) 2003-04-01
RU2264215C2 (ru) 2005-11-20
EP1913944A1 (en) 2008-04-23
PE20011030A1 (es) 2001-10-31
NO20022680L (no) 2002-08-12
HUP0301122A3 (en) 2005-03-29
IL149496A (en) 2009-12-24
TR200402293T2 (tr) 2004-10-21
CA2388959A1 (en) 2001-06-14
MY133423A (en) 2007-11-30
WO2001041748A2 (en) 2001-06-14
DE60019814T2 (de) 2006-03-02

Similar Documents

Publication Publication Date Title
IL149496A0 (en) Pharmaceutical combinations and their use in treating gastrointestinal disorders
AU2001293553A1 (en) Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment
EP0924983A4 (en) S (-) - TOLTERODINE FOR THE TREATMENT OF URINARY AND GASTROINTESTINAL DISORDERS
IL156678A0 (en) Glucopyranosyloxypyrazole derivatives and use thereof in medicines
IL144954A0 (en) Quinazolines and therapeutic use thereof
IL151946A0 (en) 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
HUP0203430A3 (en) Quinazolinones and their use
GB9721437D0 (en) Heteroaromatic compounds and their use in medicine
HUP0400069A3 (en) Pharmaceutical combinations and their use in preventing and treating the thrombosis
SI1143997T1 (en) Tumor necrosis factor antagonists and their use in endometriosis treatment
AU2002243363A8 (en) Use of aziridino-compounds in the treatment of immune dysfunctions
ZA97741B (en) Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders.
AU2001266229A1 (en) Hcn polypeptides and polynucleotides and their use in therapy
GB2370233B (en) Apparatus for use in behaviour modification and the like
HUP0301553A3 (en) Pharmaceutical compositions and their use for treating neurological disorders
PL363048A1 (en) Azabicyclic derivatives and their therapeutic use
HUP0105351A3 (en) Effervescent laxatives and their use
SI1286668T1 (en) Pharmaceutical combinations comprising tegaserod und omeprazole and their use in treating gastrointestinal disorders
AU6330300A (en) Use of interleukin-6 in treatment of obesity and/or obesity associated disorders
HUP0105203A3 (en) S-nitrosothiols as agents for the treatment of circulatory dysfunctions and their use
GB9929581D0 (en) Comjpositions and their use
GB9903919D0 (en) Aminophenols and their therapeutic use
HUP0201800A2 (en) Novel calpains and their use
HUP9900045A3 (en) Improved leukaemic blood-based product and their use in therapy
GB0026428D0 (en) Hydroimidazolone derivatives and their use in therapy